NCT06876142 2026-03-19
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
Clinical Trials
9 trialsNCT06843967 2026-03-13
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT05983159 2026-02-19
TARGET-VM
Murdoch Childrens Research Institute
Phase 2 Recruiting
NCT06693284 2026-02-03
A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]
University of Minnesota
Phase EARLY_PHASE1 Recruiting
NCT07237100 2025-11-19
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Sutter Health
Phase 2 Recruiting
NCT03962543 2025-08-07
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
NCT02039336 2025-07-08
M13DAP
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT05054374 2025-05-23
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT06159166 2025-04-23
Mirda
Johns Hopkins University
Phase 1/2 Recruiting